Compare Mesoblast Limited (MESO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Merck & Co., Inc. — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Merck & Co., Inc. trades at $125.52 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 141.6× Mesoblast Limited's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | MRK | |
|---|---|---|
Market Cap | $2.17B | $307.25B |
Sector | Technology | Health |
52-Week High | $20.96 | $129.52 |
52-Week Low | $12.88 | $77.60 |
Enterprise Value | $2.17B | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Merck (MRK) trades at $125.44, down 1.62% on the day, with a neutral technical signal. The company reported strong 2025 results with revenue of $65.01B and net income of $18.25B, though Q1 2026 saw a loss. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing positions. Valuation ratios include a P/E of 35.04 and ROE of 18.97%, indicating solid profitability but premium pricing.
Outlook remains positive with a consensus price target of $137.30, reflecting 9.5% upside potential. Risks include rising debt levels and competitive pressures in pharma. Analyst sentiment is bullish with 68% buy ratings, supporting a favorable investment case amid ongoing strategic acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
